Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus anthracycline-taxane chemotherapy in early-stage triple-negative breast cancer
2018-001155-13Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Dec 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathologic complete response in breast and axillary lymph nodes (ypT0/ypN0). Started Dec 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001155-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001155-13.